TVGN Tevogen Bio Holdings Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q May 15, 2026TVGN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
TVGN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| March 6, 2026 | 1-for-50 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| Dec. 31, 2025 | $-1.45 | $-2.04 | 28.9% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
We don't have SEC filings for this ticker yet.
Per Share
| Metric | Trend | Q4 2026 |
|---|---|---|
| EPS (TTM) | $-4.92 |
Valuation (TTM)
| Metric | Trend | Q4 2026 |
|---|---|---|
| Revenue TTM | $-196.1K | |
| Net Income TTM | $-27M | |
| P/E | -0.9 | |
| Earnings Yield | -108.9% |
Most recent period on the left · null values shown as ·
Institutional owners (13F) 1 filer · $375K total · As of Dec. 31, 2025
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 7 (+4 vs prior Q) | 9 (+3 vs prior Q) | 24 (+6 vs prior Q) | 9 (-13 vs prior Q) | +252K |
Compared to Q3 2025. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $375,269 | 1,133,745 | 100.00% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Ryan H. Saadi ×3 filings | Dec. 16, 2025 | 62.00% | Amendment | · | SEC |
| Kirti Desai | Feb. 22, 2024 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Surendra Ajjarapu | July 7, 2023 | · | Initial filing | Passive investment | SEC |
| Semper Paratus Sponsor LLC ×3 filings | June 8, 2023 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 11 insiders · 5 officers · 7 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ryan H. Saadi | Chief Executive Officer | Dec. 18, 2025 G | 124,284,453 | 0 | 0 | $0 |
| Surendra K Ajjarapu | CEO and Chairman | June 7, 2023 A | 8,988,889 | 0 | 0 | $0 |
| Kirti Desai | Chief Financial Officer | Dec. 11, 2025 G | 10,149,186 | 0 | 0 | $0 |
| Neal Flomenberg | Chief Scientific Officer, Global R&D Lead. All holdings herein have been adjusted to reflect the Company's 1-for-50 reverse sto | March 13, 2026 S | 76,940 | 0 | 3 | $-6,635 |
| Sadiq Khan | Chief Commercial Officer | June 27, 2025 A | 1,169,618 | 0 | 0 | $0 |
| Jeffrey L. Feike | Director | Dec. 23, 2024 A | 821,771 | 0 | 0 | $0 |
| Keow Lin Goh | Director | Dec. 23, 2024 A | 433,923 | 0 | 0 | $0 |
| Curtis L. Patton | Director | Dec. 23, 2024 A | 1,209,618 | 0 | 0 | $0 |
| Victor J. Sordillo | Director | Dec. 23, 2024 A | 576,962 | 0 | 0 | $0 |
| Susan M Podlogar | Director | Dec. 23, 2024 A | 433,923 | 0 | 0 | $0 |
| Semper Paratus Sponsor LLC | 10% owner | June 7, 2023 S | 4,294,444 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 2 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
TVGN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.